Casimersen

Generic name: Casimersen
Brand names: Amondys 45
Dosage form: intravenous solution (100 mg/2 mL)
Drug class: Miscellaneous uncategorized agents

Usage of Casimersen

Casimersen is used to treat Duchenne muscular dystrophy in adults and children who have a certain gene mutation. Your doctor will test you for this gene mutation.

Casimersen was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to casimersen, but further studies are needed.

Casimersen may also be used for purposes not listed in this medication guide.

Casimersen side effects

Get emergency medical help if you have signs of an allergic reaction: hives, itching, rash, blistering or peeling; fever; difficult breathing; swelling of your face, lips, tongue, or throat.

Casimersen may cause serious side effects. Call your doctor at once if you have:

  • pink, brown, or red urine;
  • foamy urine; or
  • swelling in your face, hands, feet, or stomach.

    • Common side effects of casimersen may include:

  • headache;
  • fever;
  • joint pain;
  • cough; or
  • cold symptoms such as stuffy nose, sneezing, sore throat.

    • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Casimersen

    Tell your doctor if you have ever had kidney problems.

    Tell your doctor if you are pregnant or breastfeeding.

    Relate drugs

    How to use Casimersen

    Usual Adult Dose for Muscular Dystrophy:

    30 mg/kg via IV infusion once a week Comments:-This drug has been approved under an accelerated approval based on an increase in dystrophin production in skeletal muscle; continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.Use: For the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

    Usual Pediatric Dose for Muscular Dystrophy:

    30 mg/kg via IV infusion once a week Comments:-This drug has been approved under an accelerated approval based on an increase in dystrophin production in skeletal muscle; continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.Use: For the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

    Warnings

    Before using casimersen tell your doctor about all your medical conditions or allergies, all medicines you use, and if you are pregnant or breastfeeding.

    What other drugs will affect Casimersen

    Other drugs may affect casimersen, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

    Popular FAQ

    The new drugs approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) are Amondys 45 (casimersen), Viltepso (viltolarsen), Vyondys 53 (golodirsen), Exondys 51 (eteplirsen), Elevidys (delandistrogene moxeparvovec), and Emflaza (deflazacort). They include antisense oligonucleotides, a glucocorticoid and a gene therapy. Duchenne muscular dystrophy (DMD) is a genetic disease that causes progressive weakness, loss of motor function and damage to skeletal and heart muscles. DMD, which has no cure, primarily affects males starting in early childhood, usually between 2 and 3 years of age. Continue reading

    The new drugs approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) are Amondys 45 (casimersen), Viltepso (viltolarsen), Vyondys 53 (golodirsen), Exondys 51 (eteplirsen), Elevidys (delandistrogene moxeparvovec), and Emflaza (deflazacort). They include antisense oligonucleotides, a glucocorticoid and a gene therapy. Duchenne muscular dystrophy (DMD) is a genetic disease that causes progressive weakness, loss of motor function and damage to skeletal and heart muscles. DMD, which has no cure, primarily affects males starting in early childhood, usually between 2 and 3 years of age. Continue reading

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords